Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
97.80    -16.80 (-14.66%)
Bid:
99.90
Ask:
100.80
Spread: 0.90 (0.901%)
Market Cap: £160.34m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Q3 Trading update

6 Nov 2017 07:00

RNS Number : 5872V
Synthomer PLC
06 November 2017
 

November 6th 2017

Q3 Trading update

Continued progress in line with expectations; Full Year 2017 outlook unchanged

Synthomer plc ('Synthomer' or 'the Group') today issues a trading update for the third quarter ('Q3') ended September 30th 2017.

Trading

Europe and North America

Europe and North America continued to trade well and in line with our expectations. Q3 reported volumes and unit margins were in line with the same period last year. On a segmental basis, we saw some weakness in Dispersions for Construction and Coatings applications but this was offset by a robust performance in Latex for the Paper and Foam markets.

Our investment programme in Germany to expand our Dispersions capacity remains on schedule for commercial production in Q3 2018.

During the quarter, we announced the acquisition of BASF's Austrian Latex business and assets for an enterprise value of €30million. The acquisition is expected to complete early in 2018 following receipt of regulatory approvals and satisfaction of other closing conditions.

Asia and Rest of World

Asia and Rest of World also continued to trade in line with our expectations. Volumes were flat versus the same period last year albeit the underlying market for Nitriles continued to grow at more than 10%. As expected, following the introduction of additional industry capacity mid 2016, unit margins were lower than Q3 2016 but have remained in line with H1 2017. Our investment plan to add further nitrile capacity at our plant in Malaysia remains on track and is expected to come on line in Q3 2018.

Foreign currency

The Group expects approximately £4m of benefit from the translation effect relating to the weakness of sterling experienced in the first half of the year. Assuming rates remain broadly unchanged for the remainder of the year, our expectation is that there will be no further benefits from currency.

Financial Position

The Group has continued to generate strong cash flows in Q3 and the balance sheet remains strong with net debt/EBITDA ratio at circa 1.3x at the end of the quarter.

FY 2017 Outlook Unchanged

We remain focused on driving sustainable growth whilst also continuing to evaluate acquisition opportunities. The Board's expectations for Full Year 2017 remain unchanged from the interim results in August, underpinned by resilient trading in Europe and the Asian Nitrile market continuing to evolve in line with our expectations.

Enquiries:

Calum MacLean, Chief Executive Officer +44 1279 436 211

Stephen Bennett, Chief Financial Officer

Charles Armitstead, Teneo Blue Rubicon +44 203 603 5220

 

The Company will hold a conference call for investors and analysts at 0800 GMT today.

Please dial: +44 (0) 808 2370030 entering conference ID: 57615130# to gain access to the call.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
QRTBIBJTMBBMBMR
Date   Source Headline
22nd Jun 20261:31 pmRNSResults of AGM
22nd Jun 20267:00 amRNSAGM trading statement
19th Jun 20267:00 amRNSDivestment of Acrylate Monomers
1st Jun 20262:42 pmRNSHolding(s) in Company
29th May 20263:57 pmRNSTotal Voting Rights
22nd May 20265:21 pmRNSNotice of AGM
8th May 20264:33 pmRNSAdmission to Trading
7th May 20261:51 pmRNSApplication for Admission to Trading
5th May 20264:25 pmRNSHolding(s) in Company
30th Apr 20264:40 pmRNSAnnual Financial Report
30th Apr 20263:17 pmRNSDirector/PDMR Shareholding
30th Apr 202611:25 amRNSDirector/PDMR Shareholding
30th Apr 20267:01 amRNSChange of Chief Financial Officer
30th Apr 20267:00 amRNSFinal Results
19th Mar 20267:00 amRNSTrading and refinancing update
11th Feb 20261:46 pmRNSStatement re potential refinancing
29th Jan 20267:00 amRNSTrading Statement - Winter 2026
27th Jan 20264:51 pmRNSHolding(s) in Company
26th Jan 20264:23 pmRNSHolding(s) in Company
18th Dec 20257:00 amRNSReceivables purchasing arrangement
12th Dec 20259:30 amRNSDirectorate change
12th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20251:28 pmRNSHolding(s) in Company
23rd Oct 20257:00 amRNSTrading statement - Autumn 2025
14th Oct 20257:00 amRNSAppointment of joint corporate broker
4th Sep 20255:17 pmRNSHolding(s) in Company
11th Aug 20258:00 amRNSDirector/PDMR Shareholding
6th Aug 20259:45 amRNSDirector/PDMR Shareholding
5th Aug 202511:57 amRNSDirector/PDMR Shareholding
5th Aug 202511:00 amRNSDirectorate Change
5th Aug 20257:00 amRNSInterim results
4th Jul 20257:01 amRNSDirector/PDMR Shareholding
1st Jul 20257:00 amRNSCovenant update
30th Jun 20257:00 amRNSDirectorate Changes
27th Jun 20254:21 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSDivestment of William Blythe completed
6th May 20257:00 amRNSDivestment of William Blythe
1st May 20254:18 pmRNSResults of AGM
1st May 20257:00 amRNSTrading Statement - Spring 2025
15th Apr 20253:00 pmRNSHolding(s) in Company
28th Mar 20257:30 amRNSDirector/PDMR Shareholding
27th Mar 20257:30 amRNSDirector/PDMR Shareholding
25th Mar 20254:23 pmRNSAnnual Report and Notice of AGM
25th Mar 202511:43 amRNSDirector/PDMR Shareholding
25th Mar 202511:41 amRNSDirector/PDMR Shareholding
24th Mar 20257:30 amRNSHolding(s) in Company
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
11th Mar 20257:00 amRNSFinal Results
6th Mar 20258:32 amRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.